Biosimilar Remicade now available in Europe
This article was originally published in Scrip
Executive Summary
The privately owned company, Alvogen, has launched Inflectra, a biosimilar version of Janssen's Remicade, in eight central and eastern EU markets. The product is being marketed under a strategic partnership with the US firm Hospira, which in turn has an agreement with the biosimilar's originator, South Korea's Celltrion.